Time from EMA approval to CT outcome for first indication vs. AMSR
This post launches a series of infographics focused on pricing and market access trends of rare disease treatments in France. Each post in this series zooms...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
Follow us on LinkedIn: CRA on Rare Disease
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
This post launches a series of infographics focused on pricing and market access trends of rare disease treatments in France. Each post in this series zooms...
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences...
CRA’s Clara Zacharko will be presenting a CRA study on an ISPOR webinar titled “The Global Socioeconomic Impact of Rare Diseases: A Call for Action” on May...
CRA is exhibiting at the conference at booth #2018. Matt Majewski presents his session titled “What is a Fair Price for a Rare Disease Therapy?”...